Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2023-07-04 Declaration of Voting R…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document details a change in shareholding and voting rights for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) on a specific date (03/07/2023). It explicitly lists the number of shares and the resulting percentage of voting rights, crossing a threshold (implied by the structure, as the total percentage is reported). This structure is characteristic of a notification regarding changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). It is not an earnings release, annual report, or a general regulatory filing fallback.
2023-07-04 English
Director's Dealing 2023
Director's Dealing Classification · 1% confidence The document details a change in shareholding percentage by Avanza Bank Holding AB for its pension subsidiary, specifically noting that a threshold for flagging (5%) has been crossed ('Flaggning sker för passerat tröskelvärde beträffande det aggregerade innehavet'). It provides exact figures for shares held and resulting voting rights percentages before and after the transaction, dated 30/06/2023. This structure—reporting changes in significant share ownership that cross regulatory thresholds—is characteristic of a Major Shareholding Notification. This aligns with the definition for 'Major Shareholding Notification' (MRQ). It is not an earnings release, annual report, or a general regulatory filing (RNS) because it is highly specific to ownership changes.
2023-07-03 Swedish
Change in number of shares and votes in Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly details a 'CHANGE IN NUMBER OF SHARES AND VOTES' following a rights issue, stating the new total number of outstanding shares and votes as of June 30, 2023. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it mentions the information is submitted for publication, the core content is the capital change data itself, not just an announcement of an attached report, making SHA a better fit than RPA or RNS. The document length is relatively short (2403 chars), but the primary purpose is reporting the change, not just announcing a separate report.
2023-06-30 English
Ändring av antalet aktier och röster i Alligator Bioscience AB
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement (2440 characters) in Swedish titled "ÄNDRING AV ANTALET AKTIER OCH RÖSTER I ALLIGATOR BIOSCIENCE AB" (Change in the number of shares and votes in Alligator Bioscience AB). It explicitly states that the number of shares and votes has changed due to the completion of a rights issue, providing the final count as of June 30, 2023. It concludes with a statement that this information is required to be disclosed under financial instrument trading laws and includes a link to a PDF document. Since the text is short and primarily serves to announce a change in the capital structure (share count) and directs the user to the full details (via the PDF link), it fits the criteria for a capital/financing update (CAP) or potentially a general regulatory filing (RNS). Given the specific nature of announcing a change in the total number of shares and votes following a financing event (rights issue), 'Capital/Financing Update' (CAP) is the most precise fit, although it also relates to share structure. However, since it details a direct change in the number of shares outstanding, SHA (Share Issue/Capital Change) is also highly relevant. Comparing CAP (fundraising/financing activities) and SHA (new share issues/capital changes), the document explicitly details the result of a rights issue (a financing activity resulting in new shares). SHA is often used for stock splits or new issues. Given the context of a rights issue completion leading to a change in the total share count, SHA is the most accurate classification for reporting the resulting share structure change. It is not a general announcement of a report (RPA) but the report itself (a mandatory disclosure of share structure change).
2023-06-30 Swedish
Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Earnings Release Classification · 1% confidence The document is a press release announcing positive second interim efficacy analysis results from a Phase 2 clinical study (OPTIMIZE-1) for the drug mitazalimab. It details efficacy metrics (ORR, DoR) and includes quotes from the CEO and investigator. Crucially, the final section states: "*This information is information that Alligator Bioscience is obliged to make public pursuant to the EU Market Abuse Regulation.*" and includes an attachment link to the full announcement PDF. This structure—a brief announcement summarizing key data points and pointing to the full release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is focused purely on clinical trial results and not periodic financial performance (like revenue/net income), it is best classified as an announcement of material information. Given the context of clinical trial updates being material, and the lack of a specific category for 'Clinical Trial Results Announcement', the most appropriate general regulatory category is RNS (Regulatory Filings), as it is a mandatory public disclosure under EU regulations (MAR). It is not an ER (which focuses on financial performance), nor is it an IP (Investor Presentation) or CT (Call Transcript). It is a formal regulatory disclosure. FY 2023
2023-06-26 English
Alligator Bioscience tillkännager positiva effektdata från den andra interimsanalysen från fas 2-studien OPTIMIZE-1 med mitazalimab i bukspottkörtelcancer
Legal Proceedings Report Classification · 1% confidence The document is a press release from Alligator Bioscience announcing positive updated interim results from their Phase 2 clinical trial (OPTIMIZE-1) regarding the drug mitazalimab for pancreatic cancer. It details efficacy data (ORR, DoR) and mentions future regulatory discussions and the expected timeline for top-line data. The text concludes with a statement indicating that the information is being made public under the EU Market Abuse Regulation and provides a link to the full PDF document. Since this is an announcement about clinical trial results and progress, it is not a full Annual Report (10-K), a formal Earnings Release (ER), or a comprehensive Interim Report (IR). It is a specific type of corporate update. Given the options, this type of announcement, which details clinical trial progress and data updates, often falls under general Regulatory Filings (RNS) or, if it were a more formal presentation, Investor Presentation (IP). However, since it is a direct press release announcing specific data points and progress updates, and it is not explicitly a management discussion (MDA) or a formal earnings report, the most appropriate general category for significant, non-standard regulatory news that doesn't fit elsewhere is RNS (Regulatory Filings). It is not short enough to be a pure RPA, as it contains substantial detail, but it is an announcement of data rather than the final comprehensive report itself. Given the context of clinical trial updates, RNS is the best fit as a general regulatory announcement.
2023-06-26 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.